A $10bn Target: Stelara Sales Break Barrier Ahead Of Biosimilar Launches

Ustekinumab Brand Grows By More Than A Tenth In Final Year Before Competition

 
• By Dave Wallace

With competition to Stelara due to kick in midway through 2024, the brand now represents a $10bn+ target for biosimilars, according to the latest figures from J&J.

Target growing from 2021 to 2023
Stelara represents a growing target for biosimilars • Source: Shutterstock

More from Earnings

More from Business